About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IMMU - Immunomedics| Previous Close | $87.86 | Open | |
| Volume | Market Cap | 20.309B | |
| Yield | Last Dividend |
| Head to Head Analysis: OncoCyte (NYSE:OC... | 10/24/20 |
| OncoCyte (NYSE:OCX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the better business? We will contrast the two businesses b... | |
| Gilead Sciences Closes Immunomedics Purc... | 10/23/20 |
| The two companies announced the $21 billion acquisition last month. | |
| Gilead Sciences Completes Acquisition of... | 10/23/20 |
| FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to a... | |
| The Daily Biotech Pulse: Gilead Gets Ful... | 10/23/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Ami... | |
| The Daily Biotech Pulse: Prothena Progre... | 10/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Ail... | |
| Immunomedics (NASDAQ:IMMU) Reaches New 1... | 10/20/20 |
| Immunomedics, Inc. (NASDAQ:IMMU) shares reached a new 52-week high on Tuesday . The stock traded as high as $87.70 and last traded at $87.68, with a v... | |
| The Daily Biotech Pulse: Vertex Pulls Pl... | 10/15/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X... | |
| Gilead Sciences Announces Expiration of ... | 10/14/20 |
| FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodin... | |
| Antibody Drug Conjugate Market, Top key ... | 10/12/20 |
| Antibody Drug Conjugate Market Size, Status and Forecast 2026 The Antibody Drug Conjugate Market Research Report is a valuable source of insightful da... | |
| Cancer Immunotherapy Market Year: 2020-2... | 10/12/20 |
| A report by The Insight Partner's on the Cancer Immunotherapy Market discusses the growth of the market in great detail. It discusses thoroughly all f... | |
| Growing M&A momentum drives gains in Rhe... | 10/12/20 |
| Growing M&A momentum drives gains in Rhenman???s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activi... | |
| Gilead Sciences: Debt Fueled Bottom (NAS... | 09/25/20 |
| Gilead Sciences paid a hefty premium for Immunomedics. The breast cancer drug deal is expected to be accretive to EPS by 2023. | |
| The Week Ahead In Biotech: Conference Pr... | 09/20/20 |
| Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccin... | |
| High Hopes for Amgen and Gilead at Europ... | 09/18/20 |
| Europe???s biggest conference for cancer researchers will be a virtual affair this weekend, but it is still expected to be a big deal for companies li... | |
| Immunomedics Announces Encouraging Early... | 09/18/20 |
| Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) | |
| Wachtell regains top M&A perch, leapfrog... | 09/17/20 |
| With the fourth quarter fast approaching, Wachtell, Lipton, Rosen & Katz has passed Latham & Watkins to once again become the top U.S. M&A adviser bas... | |
| Gilead: Markets Like Deal For Immunomedi... | 09/15/20 |
| Gilead is buying Immunomedics for Trodelvy. CEO Daniel O'Day has seen data to be presented at upcoming oncology conference. | |
| Monoclonal Antibodies: A Good Place To B... | 09/15/20 |
| The market is crazy high by most measures. Gilead's intention to buy Immunomedics for $21 billion shows the upside of monoclonal antibodies. | |
| What will it take for Gilead to break ev... | 09/15/20 |
| The deal, which gives Gilead control of Immunomedics, came at a more than 100% premium to the latter firm's most recent stock price. | |
| Futures Power Higher On Upbeat Chinese, ... | 09/15/20 |
| Futures Power Higher On Upbeat Chinese, German Data Tyler Durden Tue, 09/15/2020 - 07:59 US equity futures and world stocks continued their ramp highe... | |
| The Daily Biotech Pulse: Marinus Epileps... | 09/15/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ave... | |
| Merger Arbitrage Mondays - Gilead Scienc... | 09/14/20 |
| Merger activity decreased last week, with two new deals announced. The acquisition of Immunomedics by Gilead Sciences. | |
| SHAREHOLDER ALERT: WeissLaw LLP Investig... | 09/14/20 |
| NEW YORK, Sept. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of... | |
| Stock Market Today: Big Deal! Big Deal! ... | 09/14/20 |
| A roaring day of M&A and other tie-ups helped inject some life into the stock market Monday, as did renewed hopes for a successful vaccine before the ... | |
| What Gilead's $21 Billion Oncology Bet M... | 09/14/20 |
| Gilead makes a major oncology play, spending $21 billion on Immunomedics. When will the deal be accretive, and what does this mean? Gilead seems like ... | |
| IMMUNOMEDICS INVESTOR ALERT by the Forme... | 09/14/20 |
| NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (???KSF???) a... | |
| Gilead Sciences And Immunomedics: Buy Po... | 09/14/20 |
| Gilead Sciences has announced it's buying Immunomedics for $21 billion - we don't expect the market to react favorably. | |
| Gilead Analysts Dissect Immunomedics Dea... | 09/14/20 |
| Gilead Sciences, Inc. (NASDAQ: GILD ) announced over the weekend a deal to buy Immunomedics, Inc. Latest Ratings for ??? Full story available on Benzi... | |
| Stocks making the biggest moves midday: ... | 09/14/20 |
| Oracle, Nvidia and Immunomedics were all up on dealmaking news. Overstock got a boost after an analyst upgrade. | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Portfolio | TraderCZ | 99.00 % | Subscribe |
| Lewis Aung's long pick | Kyaw Aung | 69.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| smashingdon | Paul | 63.00 % | Follow |
| Hi America | Lawrence | 62.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
